Halozyme Therapeutics, Inc., San Diego, CA
Darin Taverna , Marie Printz , Michael J. LaBarre , Rose E. Sekulovich
Background: Hyaluronan (HA) can be a constituent of the tumor microenvironment (TME). Accumulation of HA in the TME may result in elevated interstitial pressure, vascular compression, hypoxia, and reduced drug delivery and immune cell access. Pegvorhyaluronidase alfa (PEGPH20; PVHA) enzymatically degrades HA, potentially increasing access and antitumor efficacy of cytotoxic and immuno-therapies. Liquid biopsies may provide a non-invasive approach to predict therapeutic efficacy of PVHA. Methods: Total plasma HA was analyzed as a pharmacodynamic biomarker for PVHA activity in HALO 109-202 (NCT01839487), a Phase 2, open-label, two-stage randomized study of PVHA + nab-paclitaxel + gemcitabine (PAG) vs AG only, in previously untreated patients with Stage IV metastatic PDAC. HA was measured with a liquid chromatography-tandem mass spectrometry (LC-MS/MS) disaccharide assay using baseline plasma samples from Stage 1 (n = 132) and Stage 2 (n = 128) of the study. Results: Lower baseline plasma HA values were significantly correlated with survival outcomes, predicting progression-free survival (PFS) benefit in PVHA-treated patients in Stages 1 and 2, and overall survival (OS) benefit in PVHA-treated patients in Stage 2 (Table). Conclusions: These results support further exploration of a liquid biopsy-based companion diagnostic (CDx) for predicting the therapeutic efficacy of PVHA.
Endpoint | Stages | Cutoff | Percent Potential Responders ≤ Cutoff | KM PAG&AG P-value, Likelihood Ratio Test | HR (95% CI) | Median Surv. Diff. PAG-AG (95% CI, bootstrapped) |
---|---|---|---|---|---|---|
PFS | Stages 1 & 2 | 99 ng/mL | 38% | 0.025 | 0.55 (0.33-0.91) | 2.6 mo (0-4.6) |
OS | Stage 2 | 124 ng/mL | 63% | 0.017 | 0.48 (0.27-0.86) | 3.4 mo (0.2-8.7) |
CI, confidence interval; HR, hazard ratio; KM, Kaplan-Meier.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Devalingam Mahalingam
2018 ASCO Annual Meeting
First Author: Song Wang
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Anita Ahmed Turk
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Derek B. Grose